FDA RFI: Enterprise IT Application Development (EAD) BPA to Centralize, Streamline, and Rationalize Acquisition Vehicles for IT Solutions

Notice ID: FDA-RFI-75F40124Q00156

The U.S. Food and Drug Administration (FDA) is issuing this RFI as a means of conducting market research, pursuant to Federal Acquisition Regulation (FAR) Part 10 Market Research, to identify potential stakeholders from the marketplace capable of providing professional Information Technology (IT) services for the FDA Enterprise IT Application Development (EAD) Blanket Purchase Agreement (BPA).

BPA Scope:  The FDA CIO’s office is performing market research for an EAD BPA strategic acquisition vehicle to centralize, streamline, and rationalize acquisition vehicles for all the IT solutions development across FDA to implement governance, standardization, monitoring, tracking, reporting, and managing of all FDA IT investments to support the mission and functions of the organization. Overall, the EAD Strategic Acquisition vehicle goals are:

• Expand sharing of FDA-wide buying data, leading to better-informed business decisions.
• Maximize FDA’s shared purchasing power, allowing FDA to leverage volume discounts.
• Maximize FDA’s purchasing efficiencies by reducing administrative costs and contract duplications.

BPA Objectives: Through this BPA, the Government seeks to achieve the following objectives:

• Establish a strategic acquisition vehicle used for all IT application development across FDA. 2) Establish centralized governance and oversight to meet the HHS and FDA CIO Information Technology Acquisition Review (ITAR) and Federal Information Technology Acquisitions and Reform Act (FITARA) objectives.
• Accelerate and support Business process transformation to develop/implement innovative enterprise business solutions to achieve OneFDA vision.
• Improve compliance with OMB directive of Category management and Spend Under Management initiative.
• Improve alignment with OMB directive of enterprise architecture.
• Improve Socio-economic goals alignments.
• Improve efficiencies and cost reduction through economies of scale.
• Reduce the overall Operations and Maintenance (O&M) expenditures by an average of 5% via improved efficiency and innovation each year during the life of the contract.
• Establish enterprise IT development standards, tools, technologies, processes, deployment, and reports to control siloed development and practices.
• Deploy cutting edge technology, solutions, and services to improve efficiencies and user experience.
• Accelerate implementation of hybrid Cloud-based systems and solutions.
• Enhancement of system integration, consolidation, standardization, usability, and data flow to down-stream systems enabling the FDA to utilize resources, processes, and systems to achieve a seamless integration of FDA projects.
• Obtain services to develop, integrate, consolidate, and maintain enterprise solution for the financial management, Human resource management, acquisition management, businesses processes, and customer services using innovative technology, project management, administration, and change management techniques.
• Increase access to resources that are trained and equipped to guide the appropriate application of tools and techniques to assist FDA leadership in more effectively and efficiently completing high profile projects, managing programs, and improving the culture of the teams.
• Increase use of evidence-based, data-driven, and risk-based decision making, including facts and benchmarks to scope the opportunity and measure results.

The anticipated BPA period of performance is Five (5) Years in Total.

Read more here.

🔊 Listen to Story